Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 6,067 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

NCT04797650
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543 matching placebo, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

NCT01156597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 23, 2026, 6:10 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Acceptance and Mindfulness for Exercise in Anxiety

NCT03818789
View directory record Official record
Conditions
Anxiety
Interventions
Mindfulness and acceptance training, Study skills video
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 23, 2026, 6:10 PM EDT
Recruiting Phase 3 Interventional

A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

NCT07281079
View directory record Official record
Conditions
Phelan-McDermid Syndrome
Interventions
NNZ-2591, Placebo
Drug
Lead sponsor
Neuren Pharmaceuticals Limited
Industry
Eligibility
3 Years to 12 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Glendale, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

MBSR During AI Therapy for Breast Cancer

NCT03253627
View directory record Official record
Conditions
Breast Cancer, Cognitive Symptom
Interventions
Health Enhancement Program, Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma

NCT04502862
View directory record Official record
Conditions
Asthma
Interventions
SAR231893, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Bakersfield, California • Culver City, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 2 Interventional

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

NCT01096862
View directory record Official record
Conditions
Psoriasis
Interventions
peficitinib, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

NCT05896527
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DC-806, Placebo
Drug · Other
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Fountain Valley, California • Santa Monica, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 6:10 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT04915950
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Temanogrel, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Not applicable Interventional

Transcranial Direct Current Stimulation and Effects on Early Auditory Processing in Schizophrenia

NCT03537703
View directory record Official record
Conditions
Schizophrenia
Interventions
Active tDCS + Auditory Training, Active tDCS + Control Condition, Sham tDCS + Auditory Training
Combination Product
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04619797
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Strength, Aging, and Memory in Prostate Cancer

NCT04852224
View directory record Official record
Conditions
Prostate Neoplasm, Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 6:10 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

NCT04064346
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, ADPKD
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
Palladio Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 23, 2026, 6:10 PM EDT
Recruiting Phase 3 Interventional

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546
View directory record Official record
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Recruiting Phase 2 Interventional

Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

NCT07734103
View directory record Official record
Conditions
Stuttering, Adult
Interventions
Lumateperone (ITI-007), Placebo Tablet or Capsule
Drug
Lead sponsor
CSTrials Inc.
Network
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Results available

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05216224
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
ATI-450, Placebo oral tablet
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Not applicable Interventional Results available

Southeastern Collaboration to Improve Blood Pressure Control

NCT02866669
View directory record Official record
Conditions
Hypertension
Interventions
Practice Facilitation, Peer Coach, Enhanced usual care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
1,592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 23, 2026, 6:10 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD9550, AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 3 Interventional Results available

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

NCT02291679
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
95
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 23, 2026, 6:10 PM EDT
Terminated Phase 2 Interventional

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

NCT01489046
View directory record Official record
Conditions
HIV-1 Infection
Interventions
BMS-986001, Placebo matching with BMS-986001, Efavirenz, Lamivudine, Tenofovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
Sacramento, California • Orlando, Florida • West Palm Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 23, 2026, 6:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

NCT00656097
View directory record Official record
Conditions
Rabies
Interventions
CL184, HRIG, Placebo matching CL184
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
19 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 23, 2026, 6:10 PM EDT